Adjusted EBITDA of USD 35 million to USD 38 million
165 to 170 active programs by the end of Q3
Q2 2026 earnings call highlights
Paysign held its Q2 2026 earnings call with CEO Mark Newcomer, CFO Jeff Baker, President of Patient Affordability Matt Turner, and Chief Payments Officer Matt Lanford.
Revenue rose 48.1% to USD 28.3 million.
Net income reached USD 6.8 million.
Gross margin expanded 170 bps to 63.3%.
Patient affordability and plasma revenue growth
Patient affordability revenue climbed 88.9% to USD 14.6 million.
PAYS•
